SYRE - Spyre Therapeutics, Inc.
IEX Last Trade
23.37
-5.580 -23.877%
Share volume: 0
Last Updated: Tue 24 Dec 2024 06:25:52 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
35.29%
PREVIOUS CLOSE
CHG
CHG%
$28.95
-5.58
-19.27%
Fundamental analysis
35%
Profitability
50%
Dept financing
14%
Liquidity
75%
Performance
16%
Performance
5 Days
-2.18%
1 Month
-16.07%
3 Months
-15.77%
6 Months
1.08%
1 Year
28.45%
2 Year
60.97%
Key data
Stock price
$23.37
DAY RANGE
$23.52 - $28.95
52 WEEK RANGE
$20.72 - $47.97
52 WEEK CHANGE
$15.54
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/07/2024
Company detail
CEO: Jeffrey M. Goldberg
Region: US
Website: aeglea.com
Employees: 100
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: aeglea.com
Employees: 100
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Aeglea BioTherapeutics, Inc. designs and develops human enzyme therapeutics for the treatment of patients and families with rare metabolic diseases. The company's lead product candidate is pezilarginase, a recombinant human Arginase 1 that is in Phase III PEACE trial. It also develops AGLE-177, a polyethylene glycol modified, which is in clinical trials for homocystinuria.
Recent news